eMed completed the acquisition of Science 37 for $38m.

eMed, a provider of on-demand virtual care and treatment for consumers, completed the acquisition of Science 37, a clinical research company, for $38m. “After an extensive review of opportunities available to Science 37, we believe that eMed provides the greatest value to our stockholders, customers, patients, and employees. Stockholders will receive a premium, trial sponsors will gain greater access to patients, faster enrollment, and confidence in the Company’s capital position, and our employees will be able to continue to pursue the existing mission of the Company,” David Coman, Science 37 CEO.